Mediwound Ltd (NASDAQ:MDWD) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $9.80.

MDWD has been the topic of several research reports. Zacks Investment Research cut shares of Mediwound from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Oppenheimer set a $10.00 price objective on shares of Mediwound and gave the company a “buy” rating in a research report on Thursday, November 16th. Jefferies Group set a $10.00 price objective on shares of Mediwound and gave the company a “buy” rating in a research report on Friday, August 25th. Cowen initiated coverage on shares of Mediwound in a research report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective on the stock. Finally, ValuEngine cut shares of Mediwound from a “sell” rating to a “strong sell” rating in a research report on Friday, September 22nd.

Hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN increased its stake in Mediwound by 23.5% in the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 12,522 shares during the last quarter. Renaissance Technologies LLC increased its stake in Mediwound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares during the last quarter. Nationwide Fund Advisors acquired a new stake in Mediwound in the 3rd quarter valued at $1,538,000. Alyeska Investment Group L.P. acquired a new stake in Mediwound in the 3rd quarter valued at $2,140,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in Mediwound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares during the last quarter. Hedge funds and other institutional investors own 29.46% of the company’s stock.

Shares of Mediwound (NASDAQ MDWD) opened at $4.65 on Wednesday. Mediwound has a 52-week low of $4.15 and a 52-week high of $8.25.

COPYRIGHT VIOLATION NOTICE: “Mediwound Ltd (MDWD) Receives Consensus Rating of “Buy” from Analysts” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://theolympiareport.com/2017/12/06/mediwound-ltd-mdwd-receives-consensus-rating-of-buy-from-analysts.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.